Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.

Li Z, Richards S, Surks HK, Jacobs A, Panzara MA.

Clin Exp Immunol. 2018 Dec;194(3):295-314. doi: 10.1111/cei.13208. Epub 2018 Oct 1.

2.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

3.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

4.

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.

Radue EW, Sprenger T, Gaetano L, Mueller-Lenke N, Cavalier S, Thangavelu K, Panzara MA, Donaldson JE, Woodward FM, Wuerfel J, Wolinsky JS, Kappos L.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 9;4(5):e390. doi: 10.1212/NXI.0000000000000390. eCollection 2017 Sep.

5.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

6.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

7.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

8.

Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development.

Zaratin P, Comi G, Coetzee T, Ramsey K, Smith K, Thompson A, Panzara M.

Trends Pharmacol Sci. 2016 Oct;37(10):808-810. doi: 10.1016/j.tips.2016.07.005. Epub 2016 Aug 20.

9.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
10.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
11.

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.

Baker DP, Pepinsky RB, Brickelmaier M, Gronke RS, Hu X, Olivier K, Lerner M, Miller L, Crossman M, Nestorov I, Subramanyam M, Hitchman S, Glick G, Richman S, Liu S, Zhu Y, Panzara MA, Davar G.

J Interferon Cytokine Res. 2010 Oct;30(10):777-85. doi: 10.1089/jir.2010.0092. Review.

PMID:
20836711
12.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
13.

Natalizumab and central nervous system lymphoma: no clear association.

Bozic C, LaGuette J, Panzara MA, Sandrock AW.

Ann Neurol. 2009 Sep;66(3):261-2. doi: 10.1002/ana.21835. No abstract available.

PMID:
19798645
14.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
15.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.

Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.

16.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
17.

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators.

Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69.

18.

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, Lynn F, Jurgensen S, Woodworth J, Goelz S, Duda PW, Panzara MA, Ransohoff RM, Fox RJ.

Neurology. 2009 Feb 3;72(5):402-9. doi: 10.1212/01.wnl.0000341766.59028.9d.

19.

More on melanoma with transdifferentiation.

Panzara MA, Bozic C, Sandrock AW.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. No abstract available.

PMID:
18596284
20.

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire.

Benedict RH, Duquin JA, Jurgensen S, Rudick RA, Feitcher J, Munschauer FE, Panzara MA, Weinstock-Guttman B.

Mult Scler. 2008 Aug;14(7):940-6. doi: 10.1177/1352458508090923. Epub 2008 Jun 23.

PMID:
18573822
21.

Natalizumab for the treatment of relapsing multiple sclerosis.

Rudick RA, Panzara MA.

Biologics. 2008 Jun;2(2):189-99.

22.

Evaluating human T cell receptor gene expression by PCR.

Gussoni E, Panzara MA, Steinman L.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.26. doi: 10.1002/0471142735.im1026s22. Review.

PMID:
18432691
23.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH.

Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Erratum in: Ann Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas].

PMID:
18383069
24.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group.

N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.

25.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29.

PMID:
17761550
26.

Health-related quality of life in multiple sclerosis: effects of natalizumab.

Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Ann Neurol. 2007 Oct;62(4):335-46.

PMID:
17696126
27.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2007 Apr 24;68(17):1390-401.

PMID:
17452584
28.

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA.

Neurology. 2007 Apr 17;68(16):1299-304.

PMID:
17438220
29.

A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.

Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH.

J Neurol. 2007 Mar;254(3):306-14. Epub 2007 Feb 3.

PMID:
17277910
30.

Infusion-related hypersensitivity reactions during natalizumab treatment.

Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2006 Nov 14;67(9):1717-8. No abstract available. Erratum in: Neurology. 2007 Feb 6;68(6):473.

PMID:
17101921
31.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

32.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

N Engl J Med. 2006 Mar 2;354(9):899-910.

33.

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

O'Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, Miszkiel K, Khan O, Rice G, Sheremata W; International Natalizumab Trial Group.

Mult Scler. 2005 Oct;11(5):568-72.

PMID:
16193895
34.

Natalizumab and progressive multifocal leukoencephalopathy.

Adelman B, Sandrock A, Panzara MA.

N Engl J Med. 2005 Jul 28;353(4):432-3. Epub 2005 Jun 9. No abstract available.

PMID:
15947083
35.

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.

Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O'Connor P, Miller DH.

J Neurol. 2004 Apr;251(4):407-13.

PMID:
15083284
36.

Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy.

Singhal AB, Newstein MC, Budzik R, Cha JH, Rordorf G, Buonanno FS, Panzara MA.

J Neuroimaging. 2003 Jan;13(1):79-82.

PMID:
12593136
37.

T cell receptor BV gene rearrangements in the spinal cords and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Panzara MA, Gussoni E, Begovich AB, Murray RS, Zang YQ, Appel SH, Steinman L, Zhang J.

Neurobiol Dis. 1999 Oct;6(5):392-405.

PMID:
10527806
38.

Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy.

Gussoni E, Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, Steinman L.

J Immunol. 1994 Nov 15;153(10):4798-805.

PMID:
7963545
39.

Multiple sclerosis: from immunogenetics to immunotherapy.

Oksenberg JR, Panzara MA, Steinman L.

J Neurol Sci. 1993 Apr;115 Suppl:S29-37. Review. No abstract available.

PMID:
8340790
40.

Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis.

Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, Shimonkevitz R, Sherritt M, Rothbard J, Bernard CC, et al.

Nature. 1993 Mar 4;362(6415):68-70.

PMID:
7680433
41.

Analysis of the T cell repertoire using the PCR and specific oligonucleotide primers.

Panzara MA, Gussoni E, Steinman L, Oksenberg JR.

Biotechniques. 1992 May;12(5):728-35.

PMID:
1515141
42.

The polymerase chain reaction for detection of T-cell antigen receptor expression.

Panzara MA, Oksenberg JR, Steinman L.

Curr Opin Immunol. 1992 Apr;4(2):205-10. Review.

PMID:
1605910

Supplemental Content

Loading ...
Support Center